Table 1.
Baseline clinical risk factors according to baseline age and incident CHD status.
| Baseline age <65 years N = 25 042 |
Baseline age ≥65 years N = 2982 |
|||
|---|---|---|---|---|
| CHD N = 447 |
Non-CHD N = 24 595 |
CHD N = 351 |
Non-CHD N = 2631 |
|
| Age, years | 51.9 ± 4.3* | 53.0 ± 5.2 | 69.5 ± 3.7 | 69.2 ± 3.5 |
| Self-reported race, % | ||||
| White | 427 (96.8) | 23 180 (95.0) | 344 (98.6) | 2524 (97.0) |
| Black | 5 (1.1) | 477 (2.0) | 2 (0.6) | 36 (1.4) |
| Hispanic | 2 (0.5) | 269 (1.1) | 2 (0.6) | 17 (0.7) |
| Asian | 5 (1.1) | 358 (1.5) | 0 (0) | 19 (0.7) |
| Other | 2 (0.5) | 110 (0.5) | 1 (0.3) | 6 (0.2) |
| Education, % | * | ** | ||
| <4 years post high school | 288 (65.2) | 13 168 (54.5) | 249 (72.2) | 1676 (64.7) |
| Bachelor’s degree | 93 (21.0) | 5915 (24.5) | 54 (15.7) | 433 (16.7) |
| Master’s degree or Ph.D. | 61 (13.8) | 5076 (21.0) | 42 (12.2) | 480 (18.5) |
| Body-mass index, kg/m2 | 28.4 ± 5.8* | 26.0 ± 5.0 | 26.1 ± 4.8** | 25.4 ± 4.2 |
| Current smoker, n (%) | 136 (30.4)* | 2866 (11.7) | 48 (13.8)** | 216 (8.2) |
| Diabetes, n (%) | 87 (19.5)* | 556 (2.3) | 37 (10.5)* | 90 (3.4) |
| Metabolic syndrome, % | 260 (58.2)* | 5740 (23.4) | 153 (43.7)* | 759 (29.0) |
| Hypertension, % | 188 (42.1)* | 5835 (23.7) | 204 (58.1)* | 1139 (43.3) |
| Hypertension treatment, % | 112 (25.1)* | 2911 (11.8) | 113 (32.2)** | 618 (23.5) |
| Systolic blood pressure | 125 (125–135)* | 125 (115–135) | 135 (125–145)* | 125 (125–145) |
| Physical activity (<7.5 MET-h/week), % | 256 (57.3)** | 11 059 (45.0) | 172 (49.0)* | 1071 (40.7) |
| Parental MI <60 years, n (%) | 118 (26.8)* | 3558 (14.7) | 39 (11.4) | 252 (9.8) |
| Postmenopausal, % | 187 (41.2)** | 12 038 (49.0) | 351 (100) | 2631 (100) |
| Postmenopausal hormone replacement therapy use, % | 100 (22.4)* | 7590 (30.9) | 117 (33.3) | 887 (33.8) |
| Cholesterol lowering treatment, % | 38 (8.5)* | 645 (2.6) | 30 (8.6) | 185 (7.0) |
Data presented as mean ± standard deviation (age and body-mass index), median (interquartile range)(systolic blood pressure), and frequency (%) (others). Baseline age refers to age at randomization. Percentages may not total 100 due to rounding. Student t-tests (variables expressed as means), Wilcoxon rank-sum tests (variables expressed as medians), and χ2 tests (categorical variables) were used. Statistical differences presented for participants with CHD vs non-CHD.
*
P < 0.001;
**
P < 0.01; otherwise not significant (P ≥ 0.05).
See the Supplemental Methods for biomarker measurement.